Teva’s Degevma Wins FDA Approval, Joining a Crowded Field of Xgeva Biosimilars for Cancer That Reaches Bone

Teva’s Degevma, a biosimilar to Xgeva, won FDA approval for bone complications from cancer. Here’s what patients should know about cost and safety.

Have A Referral?